DR BENJAMIN TREWIN WELCOMES YOU
Personalised Precision Care
Dr. Trewin is a neurologist specialising in Multiple Sclerosis & Migraine, known for his warm and professional demeanour. He prioritises leveraging his specialised experience and emotional insight to achieve the best outcomes for every patient. Regardless of the complexity of their issues, each patient receives dedicated care and attention to ensure optimal results. His meticulousness and focus on detail are widely recognised.
SPECIALTY SERVICES
NEUROIMMUNOLOGY
Multiple Sclerosis (MS), MOGAD, Neuromyelitis optica (NMO) & Autoimmune encephalitis
Dr Trewin is a subspecialist in autoimmune neurology, he completed his MS & Neuroimmunology Fellowship at RPAH in 2018.
He is completing a PhD at Westmead, focussing on differentiating the clinical and MRI presentation of MOGAD from MS and NMO at onset.
MIGRAINE BOTOX & GON BLOCKS
Migraine, Bruxism & Occipital Neuralgia
Dr Trewin offers Botulinum Toxin therapy for headache/migraine and teeth grinding ("Bruxism") and greater and lesser occipital nerve blocks ("GON Block") for occipital neuralgia, which frequently contributes to migraine and cluster headache symptoms.
INDEPENDENT MEDICAL EXAMINER
State Insurance Regulatory Authority (SIRA) WorkCover and Motor Accident (CTP) Permanent Impairment Assessor, Authorised Health Practitioner
I serve as an Independent Medical Examiner with SIRA accreditation, functioning as a Permanent Impairment Assessor (Nervous System and Spine) for Work Cover and as an Authorised Health Practitioner (Nervous System and Spine) for Motor Accidents (CTP).
YOUR TRUSTED NEUROLOGIST
Dr Trewin completed his BAppSc (Exercise, Sport Science & Nutrition) in 2007 and MBBS in 2012 (University of Sydney).
He completed his specialty training at St. Vincent’s Hospital, Royal Prince Alfred Hospital (Multiple Sclerosis & Neuroimmunology Fellowship) and Concord Repatriation General Hospital.
He completed his PhD in Neuroimmunology (2024) and has published 5 first-author journal articles in high-impact journals on MOGAD, Neuromyelitis Optica and Autoimmune Encephalitis.
He delivered an oral platform presentation at European Committee for Treatment and Research in MS Annual Meeting 2024 on MOGAD treatment.
Benjamin has specialist expertise in managing all autoimmune neurological disorders that affect the brain and spinal cord, and has developed extensive experience in managing patients with migraine and post-traumatic headache.
Dr Trewin is an enthusiastic teacher and has taught thousands of training neurologists and doctors throughout his own training, through YouTube @iMeducation101, as a regular examiner at Sydney ClinPrep held for Basic Physician Trainees (BPTs) at St Vincent's Hospital and also via his co-founded MCQ course for the Physicians' Written Exams.
RESEARCH
BAppSc | MBBS | FRACP | PhD
MS TRIAL SUB-INVESTIGATOR
PASS (Alemtuzumab)
ESTEEM (Dimethyl Fumarate)
NMO (Eculizumab)
PREVANZ (Vitamin D in MS)
Biotin (Progressive MS)
EXPAND (Siponimod)
ENSEMBLE (Ocrelizumab)
Visionary-MS (Gold Nanocrystals - Remyelination)
MOGAD, NEUROMYELITIS OPTICA & AUTOIMMUNE ENCEPHALITIS
Trewin BP...Ramanathan S et al. MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev. 2025; doi: 10.1016/j.autrev.2024.103693
Trewin BP...Ramanathan S et al. Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse. J Neurol Neurosurg Psychiatry. 2024;333463
Trewin BP, Laue-Gizzi H, Downie J, Francis I, Ramanathan S, Hardy TA. Clinical relapse after 52 years in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Sci. 2024 doi: 10.1007/s10072-024-07877-y
Trewin BP, Freeman I, Ramanathan S, Irani SR. Immunotherapy in autoimmune encephalitis. Curr Opin Neurol. 2022;35(3):399–414.
Trewin BP...Barnett MH et al. Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Dis. 2020;43:102175.
Liyanage G, Trewin BP, Dale RC, Ramanathan S, Brilot F, et al. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024; PMID: 38290838.
Rinaldi S, Davies A, Fehmi J, Beadnall HN, Wang J, Hardy TA, ANZ MOG Study Group (Trewin BP et al.) Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurology - Neuroimmunol Neuroinflammation. 2021;8(1):e924.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, PREVENT Study Group (Trewin BP, et al.) Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD. Ann Neurol. 2021;89(6):1088–98
CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION
Trewin B, Tilling J, Levy S. 083 Response to immunosuppressive therapy in cerebral amyloid angiopathy-related inflammation. Journal of Neurology, Neurosurgery and Psychiatry. 2018;89(6):A33-A4
EARLY-ONSET DEMENTIA
Trewin, B, Baskin, J, Levy, S, Sy, J, Tisch, S, ‘CSF1R Mutation-negative Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): Genotypic Heterogeneity in an Important Cause of Early-onset Dementia’ Neurology 2019 [P2.1-024]
MIGRAINE
Day KA, Rettiganti M, Ferguson MB, Stroud CE, Trewin BP, Takeshima T, Kingston WS. Shift from chronic to episodic migraine status and high-to low-frequency episodic migraine status among patients with treatment-resistant migraine in a phase 3 Galcanezumab study. Cephalalgia. 2020;40(1);DP62
CONTACT
